Prevalence and Characterisation of Asthma Patients According to Disease Severity in Portugal
Epi-Asthma
Epi-Asthma: Prevalence and Characterisation of Asthma Patients According to Disease Severity in Portugal
1 other identifier
observational
842
1 country
37
Brief Summary
This study aims to determine the prevalence of Asthma, Difficult-to-Treat and Severe Asthma in Portugal, and characterize patients to better understand their disease characteristics, treatment profile and health care resource use to improve clinical management of the disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2021
Typical duration for all trials
37 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 30, 2021
CompletedFirst Submitted
Initial submission to the registry
November 15, 2021
CompletedFirst Posted
Study publicly available on registry
December 27, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 6, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
March 6, 2024
CompletedMarch 6, 2025
March 1, 2025
2.9 years
November 15, 2021
March 5, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Proportion of participants with asthma, difficult-to-treat asthma, and severe asthma
Ratio between the total number of participants with confirmed asthma, difficult-to-treat asthma, and severe asthma and the total number of participants
From date of inclusion until the end of the study currently planned (2,5 years)
Secondary Outcomes (26)
Subject's characteristics - Age
From date of inclusion until the end of the study currently planned (2,5 years)
Subject's characteristics - Living in a city or rural community
From date of inclusion until the end of the study currently planned (2,5 years)
Subject's characteristics - Family history
From date of inclusion until the end of the study currently planned (2,5 years)
Subject's characteristics - Comorbidities and allergies
From date of inclusion until the end of the study currently planned (2,5 years)
Subject's characteristics - Obesity
From date of inclusion until the end of the study currently planned (2,5 years)
- +21 more secondary outcomes
Eligibility Criteria
The population of study will be adult (=\> 18 years) persons registered in the Portuguese National health service patients' database. Participants will be enrolled in the study according to proportionate allocation from primary care health units that will be identified based on demographic stratification (i.e. NUTS III)
You may qualify if:
- Adults =\>18 years old registered in Portuguese National Health service patients' database of primary care units.
- Give voluntary signed informed consent,
- Ability to understand ans answer questionnaires.
You may not qualify if:
- Participants that have a physical condition that could interfere with the study assessments or prevent the participant from adequately participating in the study (e.g. mobility problems, not able to perform spirometry,…)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
- Faculdade de Medicina da Universidade do Porto - CINTESIScollaborator
- Universidade do Minho - ICVScollaborator
Study Sites (37)
Research Site
Alpendorada, Portugal, 4575-029, Portugal
Research Site
Vila Cova Da Lixa, Portugal, 4615-604, Portugal
Research Site
Aradas, 3810-437, Portugal
Research Site
Arazede, 3140-022, Portugal
Research Site
Braga, 4700-395, Portugal
Research Site
Cascais, 2750-642, Portugal
Research Site
Coimbra, 3030-790, Portugal
Research Site
Evora, 7005-389, Portugal
Research Site
Evora, 7005-451, Portugal
Research Site
Fafe, 4820-273, Portugal
Research Site
Leiria, 2410-272, Portugal
Research Site
Lisbon, 1749-080, Portugal
Research Site
Lisbon, 1769-001, Portugal
Research Site
Lisbon, 1800-192, Portugal
Research Site
Mafra, 2640-465, Portugal
Research Site
Montenegro, 8005-518, Portugal
Research Site
Oeiras, 2780-163, Portugal
Research Site
Ovar, 3880-225, Portugal
Research Site
Pinhal Novo, 2955-050, Portugal
Research Site
Ponte, 4805-273, Portugal
Research Site
Porto, 4050-046, Portugal
Research Site
Porto, 4100-203, Portugal
Research Site
Porto, 4450-021, Portugal
Research Site
Porto, 4460-282, Portugal
Research Site
Queluz, 2745-862, Portugal
Research Site
Quinta Do Conde, 2975-326, Portugal
Research Site
Ribeira de Pena, 4870-162, Portugal
Research Site
Rio de Mouro, 2635-364, Portugal
Research Site
Tavira, 8800-534, Portugal
Research Site
Tomar, 2300-469, Portugal
Research Site
Tondela, 3460-541, Portugal
Research Site
Viana do Castelo, 4900-369, Portugal
Research Site
Vila do Conde, 4480-807, Portugal
Research Site
Vila Nova da Barquinha, 2260-400, Portugal
Research Site
Vila Nova de Gaia, 4400-712, Portugal
Research Site
Vila Real, 5000-557, Portugal
Research Site
Vouzela, 3670-261, Portugal
Related Publications (1)
Jacome C, Brito D, Joao C, Lopes F, Santos J, Amorim L, Barbosa MJ, Pardal M, Teixeira P, Bernardo F, Fonseca JA, Correia-de-Sousa J. EPI-ASTHMA study protocol: a population-based multicentre stepwise study on the prevalence and characterisation of patients with asthma according to disease severity in Portugal. BMJ Open. 2022 Sep 19;12(9):e064538. doi: 10.1136/bmjopen-2022-064538.
PMID: 36123070DERIVED
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
JoĂ£o Fonseca, MD/PhD
cintesis
- PRINCIPAL INVESTIGATOR
Jaime Correia de Sousa, MD/PhD
ICVS
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 15, 2021
First Posted
December 27, 2021
Study Start
April 30, 2021
Primary Completion
March 6, 2024
Study Completion
March 6, 2024
Last Updated
March 6, 2025
Record last verified: 2025-03